BPC-157 + TB-500 (Wolverine) common uses, half-life, side effects and more

Wolverine Stack is the community name for using BPC-157 and TB-500 together for soft-tissue and injury recovery. People take the pair for tendon, ligament, muscle, and joint healing. They also use it after surgery or an acute injury. Most run it as two separate vials on different schedules. Some sellers offer a single pre-mixed vial that combines both peptides at a fixed ratio. Neither peptide is an approved medicine in any country. Both are sold as research chemicals and are banned in sport at all times.

• Tendon, ligament, muscle, and joint recovery
• Healing after surgery or an acute soft-tissue injury
• Slow-healing or chronic injuries that have not settled
• Support and repair between hard training blocks
• Gray-market recovery protocols from clinics, forums, and peptide sellers

BPC-157 once or twice daily plus TB-500 twice weekly when run as separate vials

Most people run the two peptides as separate vials on their own schedules. BPC-157 is injected at 250 to 500 mcg subcutaneously once or twice daily. TB-500 loading is about 2 to 2.5 mg subcutaneously twice weekly with reported weekly totals of 2 to 5 mg and no single agreed schedule. Maintenance steps down toward once weekly or once every two weeks. A single pre-mixed vial that combines both peptides is the common retail form. It usually holds a 1:1 ratio such as 5 mg of each or 10 mg of each. A 1 mg total dose from a 1:1 vial delivers 500 mcg of each peptide and a 2 mg total dose delivers 1 mg of each. The 500 mcg of BPC-157 sits at the top of its standalone 250 to 500 mcg range. The 500 mcg of TB-500 sits below a standalone 2 to 2.5 mg dose. A single fixed-ratio vial cannot deliver a daily BPC-157 dose and a twice-weekly TB-500 dose at the same time. Separate vials avoid that compromise.

• Separate vials are the usual default because BPC-157 and TB-500 run on different schedules
• BPC-157 is often injected near a local injury while TB-500 is treated as whole-body and injected into the abdomen or thigh
• A fixed-ratio pre-mixed vial makes both peptides rise together with every draw
• Two reconstituted vials mixed in one syringe have no published compatibility or stability data
• Community protocols usually run 4 to 8 week blocks followed by a break rather than continuous use

No combination pharmacokinetic study exists. The two peptides clear at different rates. BPC-157 clears from animal plasma in under 30 minutes and has no human measurement. No one has measured a half-life for the injected TB-500 fragment. Full-length thymosin beta-4 data should not be treated as TB-500 data.

• Injection-site redness, itching, swelling, bruising, or pain from either injected peptide
• Tiredness, mental fog, or lethargy reported by TB-500 users in the first days
• Headache, nausea, dizziness, or a brief flu-like feeling reported after a dose
• Rare reports of shortness of breath or skin darkening that each also involved other peptides
• Immune reactions to injected gray-market peptides that no human study has measured

• BPC-157

  250 to 500 mcg per subcutaneous injection once or twice daily when run separately (500 mcg per 1 mg total dose from a 1:1 pre-mixed vial)

• TB-500

  2 to 2.5 mg per subcutaneous injection twice weekly during loading when run separately (500 mcg per 1 mg total dose from a 1:1 pre-mixed vial)

BPC-157 has no identified receptor and no settled human mechanism. Animal and cell work reports that it raises the receptor VEGFR2 without raising VEGF-A itself, raises nitric oxide signaling, and moves tendon fibroblasts and collagen-producing cells. Its effect on new blood vessels runs in both directions across tissues rather than in one. TB-500 is sold as the acetylated LKKTETQ fragment of thymosin beta-4. That fragment keeps the actin-binding site and drives cell migration and new vessel growth in the laboratory. The anti-inflammatory and cell-survival actions of thymosin beta-4 sit in regions the fragment lacks and should not be assumed for TB-500. A 2024 study found the intact fragment did not speed wound healing in a cell test and only a metabolite of it did. The stated reason to combine them is complementary repair signaling. No study shows the pair outperforms either peptide alone.

Direct evidence for BPC-157 plus TB-500 is very low. No randomized trial, controlled human safety study, or combination pharmacokinetic study of the pair was found. The closest human report is an uncontrolled retrospective chart review from one clinic in which four people received BPC-157 plus thymosin beta-4 injected into the knee joint for knee pain. Its four-person combination arm, missing control group, and joint-injection route mean it says nothing about the injected soft-tissue stack. BPC-157 evidence is mostly animal and cell work traceable largely to one research group with little independent replication. TB-500 evidence rests largely on the full thymosin beta-4 protein. No human study has given the injected fragment itself for healing. Community practice supplies the dose conventions and does not establish safety or efficacy.

• BPC-157 is banned in sport under WADA section S0 and TB-500 is banned under section S2 at all times
• Neither peptide is FDA approved as a medicine and FDA briefing documents recommend against allowing either for pharmacy compounding
• People with active or recent cancer should avoid the stack because thymosin beta-4 can promote the cell migration and blood vessels that tumors use and neither peptide has human cancer-safety data
• Blood thinners, bleeding or clotting disorders, planned surgery, or a prior clot need clinician review because animal BPC-157 studies changed clotting times and liver markers
• Pregnancy and breastfeeding use should be avoided because neither peptide has any human safety data
• A vial sold as TB-500 may hold either the fragment or the full thymosin beta-4 protein and research-chemical or pre-mixed vials carry unverified purity, dose accuracy, and sterility